Literature DB >> 27030013

Neuropathological basis of nonmotor manifestations of Parkinson's disease.

Charles H Adler1, Thomas G Beach2.   

Abstract

Nonmotor manifestations of Parkinson's disease (PD) can begin well before motor PD begins. It is now clear, from clinical and autopsy studies, that there is significant Lewy-type α-synucleinopathy present outside the nigro-striatal pathway and that this may underlie these nonmotor manifestations. This review discusses neuropathological findings that may underlie nonmotor symptoms that either predate motor findings or occur as the disease progresses.
© 2016 International Parkinson and Movement Disorder Society. © 2016 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  Parkinson's disease; nonmotor signs; synuclein

Mesh:

Year:  2016        PMID: 27030013      PMCID: PMC4981515          DOI: 10.1002/mds.26605

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  72 in total

1.  Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease.

Authors:  H I Hurtig; J Q Trojanowski; J Galvin; D Ewbank; M L Schmidt; V M Lee; C M Clark; G Glosser; M B Stern; S M Gollomp; S E Arnold
Journal:  Neurology       Date:  2000-05-23       Impact factor: 9.910

Review 2.  Identifying prodromal Parkinson's disease: pre-motor disorders in Parkinson's disease.

Authors:  Ronald B Postuma; Dag Aarsland; Paolo Barone; David J Burn; Christopher H Hawkes; Wolfgang Oertel; Tjalf Ziemssen
Journal:  Mov Disord       Date:  2012-04-15       Impact factor: 10.338

3.  Relationships between age and late progression of Parkinson's disease: a clinico-pathological study.

Authors:  Peter A Kempster; Sean S O'Sullivan; Janice L Holton; Tamas Revesz; Andrew J Lees
Journal:  Brain       Date:  2010-04-05       Impact factor: 13.501

4.  Cardiac sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body disease.

Authors:  Satoshi Orimo; Takeshi Amino; Yoshinori Itoh; Atsushi Takahashi; Tohru Kojo; Toshiki Uchihara; Kuniaki Tsuchiya; Fumiaki Mori; Koichi Wakabayashi; Hitoshi Takahashi
Journal:  Acta Neuropathol       Date:  2005-06-03       Impact factor: 17.088

5.  Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease.

Authors:  P M Mattila; J O Rinne; H Helenius; D W Dickson; M Röyttä
Journal:  Acta Neuropathol       Date:  2000-09       Impact factor: 17.088

6.  Are there differences in cerebral white matter lesion burdens between Parkinson's disease patients with or without dementia?

Authors:  Sun-Ah Choi; Virgilio Gerald Hilario Evidente; John N Caviness; Holly A Shill; Marwan N Sabbagh; Donald J Connor; Joseph G Hentz; Charles H Adler; Thomas G Beach
Journal:  Acta Neuropathol       Date:  2009-12-03       Impact factor: 17.088

7.  Olfactory function in Parkinson's disease subtypes.

Authors:  M B Stern; R L Doty; M Dotti; P Corcoran; D Crawford; D A McKeown; C Adler; S Gollomp; H Hurtig
Journal:  Neurology       Date:  1994-02       Impact factor: 9.910

8.  Cognitive impairment, decline and fluctuations in older community-dwelling subjects with Lewy bodies.

Authors:  J A Schneider; Z Arvanitakis; L Yu; P A Boyle; S E Leurgans; D A Bennett
Journal:  Brain       Date:  2012-10       Impact factor: 13.501

9.  Cortical Lewy bodies and Alzheimer-type changes in patients with Parkinson's disease.

Authors:  P M Mattila; M Röyttä; H Torikka; D W Dickson; J O Rinne
Journal:  Acta Neuropathol       Date:  1998-06       Impact factor: 17.088

10.  Distribution of α-synuclein in the spinal cord and dorsal root ganglia in an autopsy cohort of elderly persons.

Authors:  Hiroyuki Sumikura; Masaki Takao; Hiroyuki Hatsuta; Shinji Ito; Yuta Nakano; Akiko Uchino; Akane Nogami; Yuko Saito; Hideki Mochizuki; Shigeo Murayama
Journal:  Acta Neuropathol Commun       Date:  2015-09-15       Impact factor: 7.801

View more
  61 in total

1.  Brain structural and functional signatures of impulsive-compulsive behaviours in Parkinson's disease.

Authors:  F Imperiale; F Agosta; E Canu; V Markovic; A Inuggi; M Jecmenica-Lukic; A Tomic; M Copetti; S Basaia; V S Kostic; M Filippi
Journal:  Mol Psychiatry       Date:  2017-03-07       Impact factor: 15.992

2.  Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome.

Authors:  Erin M Hill-Burns; Justine W Debelius; James T Morton; William T Wissemann; Matthew R Lewis; Zachary D Wallen; Shyamal D Peddada; Stewart A Factor; Eric Molho; Cyrus P Zabetian; Rob Knight; Haydeh Payami
Journal:  Mov Disord       Date:  2017-02-14       Impact factor: 10.338

3.  Regional neuropathology distribution and verbal fluency impairments in Parkinson's disease.

Authors:  Rasheda El-Nazer; Charles H Adler; Thomas G Beach; Christine M Belden; Jonathan Artz; Holly A Shill; Erika Driver-Dunckley; Shyamal H Mehta; Marwan N Sabbagh; Geidy E Serrano; Lucia I Sue; Edward Zamrini; Jared F Benge
Journal:  Parkinsonism Relat Disord       Date:  2019-05-10       Impact factor: 4.891

Review 4.  Neuronal vulnerability in Parkinson disease: Should the focus be on axons and synaptic terminals?

Authors:  Yvette C Wong; Kelvin Luk; Kerry Purtell; Samuel Burke Nanni; A Jon Stoessl; Louis-Eric Trudeau; Zhenyu Yue; Dimitri Krainc; Wolfgang Oertel; Jose A Obeso; Laura A Volpicelli-Daley
Journal:  Mov Disord       Date:  2019-09-04       Impact factor: 10.338

5.  Heterogeneous pattern of autonomic dysfunction in Parkinson's disease.

Authors:  Laurène Leclair-Visonneau; Laurent Magy; Christelle Volteau; Thomas Clairembault; Séverine Le Dily; Cécile Préterre; Arnaud Peyre; Philippe Damier; Michel Neunlist; Yann Péréon; Pascal Derkinderen
Journal:  J Neurol       Date:  2018-02-20       Impact factor: 4.849

6.  Brain atrophy in Parkinson's disease with polysomnography-confirmed REM sleep behavior disorder.

Authors:  Shady Rahayel; Malo Gaubert; Ronald B Postuma; Jacques Montplaisir; Julie Carrier; Oury Monchi; David Rémillard-Pelchat; Pierre-Alexandre Bourgouin; Michel Panisset; Sylvain Chouinard; Sven Joubert; Jean-François Gagnon
Journal:  Sleep       Date:  2019-06-11       Impact factor: 5.849

Review 7.  [New therapy approaches for Parkinson's disease].

Authors:  K Brockmann; D Berg
Journal:  Nervenarzt       Date:  2017-04       Impact factor: 1.214

8.  Differential Alterations in Metabolism and Proteolysis-Related Proteins in Human Parkinson's Disease Substantia Nigra.

Authors:  Edna Grünblatt; Josefine Ruder; Camelia Maria Monoranu; Peter Riederer; Moussa Bh Youdim; Silvia A Mandel
Journal:  Neurotox Res       Date:  2017-12-07       Impact factor: 3.911

9.  Non-motor symptoms and striatal dopamine transporter binding in early Parkinson's disease.

Authors:  Rui Liu; David M Umbach; Alexander I Tröster; Xuemei Huang; Honglei Chen
Journal:  Parkinsonism Relat Disord       Date:  2020-02-11       Impact factor: 4.891

10.  Unified Staging System for Lewy Body Disorders: Clinicopathologic Correlations and Comparison to Braak Staging.

Authors:  Charles H Adler; Thomas G Beach; Nan Zhang; Holly A Shill; Erika Driver-Dunckley; John N Caviness; Shyamal H Mehta; Marwan N Sabbagh; Geidy E Serrano; Lucia I Sue; Christine M Belden; Jessica Powell; Sandra A Jacobson; Edward Zamrini; David Shprecher; Kathryn J Davis; Brittany N Dugger; Joseph G Hentz
Journal:  J Neuropathol Exp Neurol       Date:  2019-10-01       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.